Genmab A/S (NASDAQ:GMAB) Sees Significant Growth in Short Interest

Genmab A/S (NASDAQ:GMAB) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 3,060,000 shares, an increase of 32.5% from the February 28th total of 2,310,000 shares. Currently, 0.5% of the shares of the company are sold short. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is currently 2.1 days.

Genmab A/S Price Performance

NASDAQ GMAB traded down $0.32 on Monday, hitting $19.58. 1,044,787 shares of the stock were exchanged, compared to its average volume of 958,172. The company’s 50-day moving average price is $20.89 and its two-hundred day moving average price is $21.84. The company has a market capitalization of $12.96 billion, a price-to-earnings ratio of 11.25, a P/E/G ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $30.50.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Finally, Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares during the period. Barclays PLC grew its holdings in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC increased its stake in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.